Form 4: Astrana Health Director Receives Equity Grant

Director Mitchell W. Kitayama was granted 4,991 restricted shares of Astrana Health common stock.

Summary

• Director Mitchell W. Kitayama received an equity grant of 4,991 shares of common stock.
• The grant was issued under the Issuer's 2024 Equity Incentive Plan.
• The shares are restricted and subject to a vesting schedule.
• Following this transaction, the director's total beneficial ownership is 32,837 shares.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a routine administrative filing regarding director compensation, which is neutral in terms of immediate market impact.

Positives

• Alignment of director interests with shareholders through equity-based compensation.

Negatives

• None identified.

Risks

• Vesting is contingent upon continued service until June 10, 2027, or the 2027 annual meeting.

Future Outlook

The restricted shares are scheduled to vest on the earlier of June 10, 2027, or the date of the 2027 annual meeting of stockholders.

Industry Context

StockSavvy.ai notes that equity grants to directors are standard corporate governance practices designed to align leadership incentives with long-term shareholder value in the healthcare services sector.

Comparison to Industry Standards

• The use of restricted stock units (RSUs) for director compensation is consistent with standard practices for publicly traded companies of similar market capitalization.

Stakeholder Impact

• Minor dilution impact on existing shareholders due to the issuance of new restricted shares.

Next Steps

• Vesting of the 4,991 restricted shares on June 10, 2027, or the 2027 annual meeting date.

Key Dates

Keywords

Astrana Health, ASTH, Form 4, Insider Trading, Equity Incentive Plan, Director Compensation